UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
May 21, 2007
Date of Report (Date of earliest event reported)
ANTIGENICS INC.
--------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
--------------------------------------------------------------------------------
DELAWARE 000-29089 06-1562417
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
162 Fifth Avenue, Suite 900
New York, NY 10010
(Address of principal executive offices) (Zip Code)
212-994-8200
(Registrant's telephone number, including area code)
--------------------------------------------------------------------------------
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[] Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
[] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
[] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
[] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
Item 7.01 Regulation FD Disclosure
On May 21, 2007, Antigenics Inc. announced additional
follow-up data on the company's Oncophage(R) (vitespen), a
Phase 3 investigational therapeutic cancer vaccine. The
end-of-study results, which reflect an additional 17 months'
data collection, showed that in a substantial subset of
patients (n = 362) at intermediate risk for disease
recurrence, Oncophage demonstrated a clinically significant
improvement in recurrence-free survival (RFS) of approximately
45 percent (P < 0.01; hazard ratio [HR] = 0.55). The full text
of the press release issued in connection with the
announcement is being furnished as Exhibit 99.1 to this
current report on Form 8-K.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
The following exhibit is furnished herewith:
99.1 Press Release dated May 21, 2007
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ANTIGENICS INC.
Date: May 21, 2007
By: /s/ Garo H. Armen
--------------------------------
Garo H. Armen, Ph.D.
Chairman and Chief Executive Officer
EXHIBIT INDEX
Exhibit No. Description of Exhibit
----------- ----------------------
99.1 Press Release dated May 21, 2007